TrialBlood neoplasia2026

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Uma Borate et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.